guest ::
| Home > Documents in Process > Pedigree analysis and genetic inheritance of fatal familial insomnia (FFI) in a Portuguese multigenerational family. > print |
| Home > Documents in Process > Pedigree analysis and genetic inheritance of fatal familial insomnia (FFI) in a Portuguese multigenerational family. > print |
| 001 | 281793 | ||
| 005 | 20251021092741.0 | ||
| 024 | 7 | _ | |a 10.1007/s00415-025-13432-2 |2 doi |
| 024 | 7 | _ | |a pmid:41107634 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12534306 |2 pmc |
| 024 | 7 | _ | |a 0367-004X |2 ISSN |
| 024 | 7 | _ | |a 0012-1037 |2 ISSN |
| 024 | 7 | _ | |a 0340-5354 |2 ISSN |
| 024 | 7 | _ | |a 1432-1459 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-01183 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Da Silva Correia, Angela |0 0000-0003-1903-7172 |b 0 |
| 245 | _ | _ | |a Pedigree analysis and genetic inheritance of fatal familial insomnia (FFI) in a Portuguese multigenerational family. |
| 260 | _ | _ | |a [Darmstadt] |c 2025 |b Steinkopff |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1761031580_16842 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Fatal familial insomnia (FFI) is a rare, autosomal dominant prion disease caused by a mutation in the PRNP gene, leading to the misfolding of the cellular prion protein (PrPC) into its pathogenic form (PrPSc). This results in neurodegeneration, particularly in the thalamus, a key region regulating sleep-wake cycles, which underlies the hallmark symptoms of FFI, including insomnia, autonomic dysfunctions, motor disturbances and cognitive decline. This study focuses on a Portuguese family with FFI, providing a detailed pedigree analysis spanning five generations and comprising 134 individuals, to elucidate inheritance patterns, disease onset, and clinical progression. The findings confirm the autosomal-dominant inheritance pattern and a strong familial clustering of the disease with age of onset in the late 50s (mean 57 years). Although 67% of affected individuals succumbing to the disease within months to 1.5 years, a notably 33% exhibited prolonged survival beyond the typical disease duration, exceeding proportions reported in the literature. Family members retrospectively reported prodromal symptoms, including generalized pain, headaches, tinnitus, pruritus, and behavioral changes, occurring up to five years before diagnosis. In several cases, reportedly, disease onset was associated with major phycological stressors (e.g., emotional stress or mourning). While the significance of these observations remains uncertain, they may provide insights into potential early features in this kindred. Further research integrating genomic sequencing, biomarkers, and longitudinal clinical assessments are needed to better understand the mechanisms underlying the heterogeneity of FFI and to explore potential therapeutic interventions. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a FFI |2 Other |
| 650 | _ | 7 | |a Fatal familial insomnia |2 Other |
| 650 | _ | 7 | |a Portugal |2 Other |
| 650 | _ | 7 | |a PrPC |2 Other |
| 650 | _ | 7 | |a PrPSc |2 Other |
| 650 | _ | 7 | |a Prion diseases |2 Other |
| 650 | _ | 7 | |a Prion Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a PRNP protein, human |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Insomnia, Fatal Familial: genetics |2 MeSH |
| 650 | _ | 2 | |a Insomnia, Fatal Familial: physiopathology |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Portugal |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Pedigree |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Prion Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Age of Onset |2 MeSH |
| 650 | _ | 2 | |a Disease Progression |2 MeSH |
| 650 | _ | 2 | |a Extended Family |2 MeSH |
| 700 | 1 | _ | |a Laginha, Ines |0 P:(DE-HGF)0 |b 1 |e First author |
| 700 | 1 | _ | |a Guimaraes, Susana |b 2 |
| 700 | 1 | _ | |a Dittmar, Kathrin |0 P:(DE-2719)2811355 |b 3 |
| 700 | 1 | _ | |a Schmitz, Matthias |0 P:(DE-2719)9000287 |b 4 |u dzne |
| 700 | 1 | _ | |a Castilla, Joaquin |b 5 |
| 700 | 1 | _ | |a Zerr, Inga |0 P:(DE-2719)2000058 |b 6 |e Last author |u dzne |
| 700 | 1 | _ | |a Silva-Correia, Susana |0 P:(DE-2719)9000766 |b 7 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1007/s00415-025-13432-2 |g Vol. 272, no. 10, p. 706 |0 PERI:(DE-600)1421299-7 |n 10 |p 706 |t Journal of neurology |v 272 |y 2025 |x 0367-004X |
| 856 | 4 | _ | |u https://pub.dzne.de/record/281793/files/DZNE-2025-01183.pdf |y Restricted |
| 856 | 4 | _ | |u https://pub.dzne.de/record/281793/files/DZNE-2025-01183.pdf?subformat=pdfa |x pdfa |y Restricted |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2811355 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)9000287 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2000058 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)9000766 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-10 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 920 | 1 | _ | |0 I:(DE-2719)1440011-1 |k AG Zerr |l Translational Studies and Biomarker |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a EDITORS |
| 980 | _ | _ | |a VDBINPRINT |
| 980 | _ | _ | |a I:(DE-2719)1440011-1 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|